Description

• Drive commercial assessment of the early asset pipelines especially from scientific perspectives until the BT (Brand Team) is established and ensure a smooth transition of information and assessment outcomes from NPP to the BT
• Aim to maximize the potential of new assets by assessing the candidate assets, aligning with corporate strategy, and addressing unmet medical needs in Japan from early development phase
• Evaluate assets from a medical perspective and supports decision-making in the early stages on both clinical development strategy and future commercial strategy perspectives

• Conduct literature reviews, guideline analyses, and secondary research using available databases (e.g., epidemiology reports, treatment pattern data)
• Perform quantitative market analysis utilizing syndicated data sources to estimate patient populations, treatment flows, and market dynamics
• Summarize and systematize findings into structured disease landscape reports that highlight gaps in current medical practice
• Consolidate insights from internal knowledge-sharing sessions (e.g., feedback from Medical Affairs colleagues who engage with KOLs) to strengthen internal understanding of unmet needs

• Review the TPPs prepared by Global teams against Japan-specific treatment standards and regulatory requirements
• Map out discrepancies between the global TPP and local medical practice, including endpoints, dosing regimens, or comparator relevance
• Provide medical assessments and summarize the alignment/misalignment with Japanese clinical realities (if required)

• Prepare comparative analyses of development assets against current standard of care and competing pipeline products
• Develop internal briefing reports assessing potential clinical impact, positioning, and value of the asset in the Japanese treatment landscape
• Conduct scenario modeling to evaluate how the asset may shift treatment paradigms or address patient subgroups with unmet needs
• Collaborate with internal experts (R&D, regulatory, Medical Affairs colleagues) to validate assessments and align perspectives

• Identify data gaps relevant to the Japanese market through desk-based gap analysis of available clinical and real-world evidence
• Collaborate with Medical Affairs colleagues to refine study concepts and prioritize evidence generation opportunities

• 5+ years of work experience in the pharmaceutical industry and had experience collaborating with commercial functions
• Advanced degree in medicine, pharmacy, or life sciences (Master's or PhD preferred)
• Knowledge of medical evidence evaluation and generation
• Experience collaborating with cross-functional teams in local (Japan)
• Experience collaborating with global teams/colleagues

• Experience in early-stage clinical development and strategic planning
• Strong understanding of disease mechanisms and treatment paradigms
• Both Japanese and English (business level); fluency in speaking, writing and reading

• Remote work is supported. However, applicants must be able to commute to the office flexibly when needed. Office attendance is expected on an occasional basis, typically around twice per month.